Diabetes autoimmunity

Pediatric Endocrinology: Obesity, Diabetes Mellitus, Insulin Resistance, and Hypoglycemia

Volumn , Issue , 2006, Pages 83-99

  Winter, William E ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867302183     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (228)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28(suppl 1): S37-S42.
2. Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002; 39:537-545.
3. Taylor SI, Arioglu E. Genetically defined forms of diabetes in children. J Clin Endocrinol Metab 1999; 84: 4390-4396.
4. Winter WE, Nakamura M, House DV. Monogenic diabetes mellitus in youth: the MODY syndromes. Endocrinol Metab Clin North Am 1999; 28(4):765-785.
5. van den Ouweland JM, Lemkes HH, Trembath RC, et al. Maternally inherited diabetes and deafness is a distinct subtype of diabetes and associates with a single point mutation in the mitochondrial tRNA [Leu(UUR)] gene. Diabetes 1994; 43(6):746-751.
6. Moran A. Cystic fibrosis-related diabetes: an approach to diagnosis and management. Pediatr Diabetes 2000; 1: 41-48.
7. Marshall BC, Butler SM, StoddardM, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005; 146(5):681-687.
8. Karam JH, Lewitt PA, Young CW. Insulinopenic diabetes after rodenticide (Vacor) ingestion: a unique model of acquired diabetes in man. Diabetes 1980; 29:971-978.
9. Hauser L, Sheehan P, Simpkins H. Pancreatic pathology in pentamidine-induced diabetes in acquired immunodeficiency syndrome patients. Hum Pathol 1991; 229: 926-929.
10. Yoon JW, Austin M, Onodera T, Notkins AL. Virusinduced diabetes mellitus. N Engl J Med 1979; 300: 1173-1179.
11. Forrest JM, Menser MA, Burgess JA. High frequency of diabetes mellitus in young adults with congenital rubella. Lancet 1971; 2:332-334.
12. Cabrera-Rode E, Sarmiento L, Molina G, et al. Islet cell related antibodies and Type 1 diabetes associated with echovirus 30 epidemic: a case report. J Med Virol 2005; 76(3):373-377.
13. Elias D, Cohen IR, Schechter Y, Spirer Z, Golander A. Antibodies to insulin receptor followed by anti-idiotype antibodies to insulin in child with hypoglycemia. Diabetes 1987; 36:348-354.
14. Virally ML, Timsit J, Chanson P, Warnet A, Guillausseau PJ. Insulin autoimmune syndrome: a rare cause of hypoglycaemia not to be overlooked. Diabetes Metab 1999; 25(5): 429-431.
15. Winter WE, Signorino MR. Diabetes Mellitus: Pathophysiology, Etiologies, Complications, Management, and Laboratory Evaluation. Washington, DC: AACC Press, 2002:1-137.
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
17. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
18. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342:381-389 [Erratum: N Engl J Med 2000; 342:1376].
19. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N Engl J Med 2005; 353(25):2643-2653.
20. Kukreja A, Maclaren NK. Autoimmunity and diabetes. J Clin Endocrinol Metab 1999; 84(12):4371-4378.
21. Kawasaki E, Gill RG, Eisenbarth GS. Type 1 diabetes mellitus. In: Eisenbarth GS, ed. Endocrine and Organ Specific Autoimmunity. Austin, TX: RG Landes Company, 1999:149-182.
22. Badenhoop K, Boehm BO. Genetic susceptibility and immunological synapse in Type 1 diabetes and thyroid autoimmune disease. Exp Clin Endocrinol Diabetes 2004; 112(8):407-415.
23. Ziegler AG, Hummel M, SchenkerM, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with Type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999; 48(3):460-468.
24. Cilio CM, Bosco A, Moretti C, et al. Congenital autoimmune diabetes mellitus. N Engl J Med 2000; 342(20): 1529-1531.
25. Lampeter EF, Homberg M, Quabeck K, et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993; 341(8855):1243-1244.
26. Almawi WY, Tamim H, Azar ST. Clinical review 103: T helper Type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. J Clin Endocrinol Metab 1999; 84(5):1497-1502.
27. Gepts W, Lecompte PM. The pancreatic islets in diabetes. Am J Med 1981; 70:105-115.
28. Foulis AK, Stewart JA. The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia 1984; 26:456-461.
29. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in Type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986; 29:267-274.
30. Logothetopoulos J, Valiquette N, Madura E, Cvet D. The onset and progression of pancreatic insulitis in the overt, spontaneously diabetic, young adult BB rat studied by pancreatic biopsy. Diabetes 1984; 33:33-36.
31. House DV, Nakamura M, Winter WE. Autoimmune markers of type I diabetes mellitus. In: Nakamura RM, Burek CL, Cook L, Folds JD, eds. ClinicalDiagnostic Immunology: Protocols in Quality Assurance and Standardization. Cambridge, MA: Blackwell Science, 1998:234-249.
32. Crisa L, Mordes JP, Rossini AA. Autoimmune diabetes mellitus in the BB rat. Diabetes Metab Rev 1992; 8(1):4-37.
33. Tochino Y. The NOD mouse as a model of type I diabetes. Crit Rev Immunol 1987; 8:49-81.
34. Atkinson MA, Leiter EH. The NOD mouse model of Type 1 diabetes: as good as it gets? Nat Med 1999; 5:601-604.
35. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4p and CD8p T-cells from diabetic versus prediabetic NOD. NON-Thy-1a donors. Diabetes 1993; 42(1):44-55.
36. Yang M, Charlton B, Gautam AM. Development of insulitis and diabetes in B cell-deficient NOD mice. J Autoimmun 1997; 10(3):257-260.
37. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of Type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345(14): 1036-1040.
38. Ziegler AG, Hillebrand B, Rabl W, et al. On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. Diabetologia 1993; 36(5):402-408.
39. Thai A-C, Eisenbarth GS. Natural history of IDDM. Diabetes Rev 1990; 1:1-14.
40. Srikanta S, Ganda OP, Jackson RA, et al. Pre-Type 1 (insulindependent) diabetes: common endocrinological course despite immunological and immunogenetic heterogeneity. Diabetologia 1984; 27:146-148.
41. Srikanta S, Ganda OP, Gleason RE, Jackson RA, Soeldner JS, Eisenbarth GS. Pre-Type 1 diabetes, linear loss of beta cell response to intravenous glucose. Diabetes 1984; 33:717-720.
42. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood Type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23(10):1516-1526.
43. Becker KG. Comparative genetics of Type 1 diabetes and autoimmune disease, common loci, common pathways? Diabetes 1999; 48:1353-1358.
44. Maclaren N, Riley W, Skordis N, et al. Inherited susceptibility to insulin-dependent diabetes is associated with HLA-DR1, while DR5 is protective. Autoimmunity 1988; 1:197-205.
45. WinterWE, MaclarenNK, RileyWJ, ClarkeDW, KappyMS, Spillar RP. Maturity-onset diabetes of youth in Black Americans. N Engl J Med 1987; 316:285-291.
46. Khalil I, Deschamps I, Lepage V, al-Daccak R, Degos L, Hors J. Dose effect of cis-and trans-encoded HLA-DQ alpha beta heterodimers in IDDM susceptibility. Diabetes 1992; 41:378-384.
47. Ronningen KS. Genetics in the prediction of insulindependent diabetes mellitus: from theory to practice. Ann Med 1997; 29:387-392.
48. Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP. Islet cell antibody-positive relatives with human leukocyte antigen DQA10102, DQB10602: identification by the Diabetes Prevention Trial-Type 1. J Clin Endocrinol Metab 2000; 85(3):1255-1260.
49. Gylling M, Tuomi T, Bjorses P, et al. B-cell autoantibodies, human leukocyte antigen II alleles, and Type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2000; 85(12):4434-4440.
50. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulindependent diabetes mellitus. Nature 1987; 329:599-604.
51. Todd JA, Acha-Orbea H, Bell JI, et al. A molecular basis for MHC class II-associated autoimmunity. Science 1990; 240:1003-1008.
52. Baisch JM, Weeks T, Giles R, Hoover M, Stastny P, Capra JD. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N Engl J Med 1990; 322:1836-1841.
53. Owerbach D, Gunn S, Ty G, Wible L, Gabby KH. Oligonucleutide probes for HLA-DQA and DQB genes define susceptibility to Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1988; 31:751-757.
54. Gutierrez-Lopez MD, Bertera S, Chantres MT, et al. Susceptibility to Type 1 (insulin-dependent) diabetes mellitus in Spanish patients correlates quantitatively with expression of HLA-DQ alpha Arg 52 and HLA-DQ beta non-Asp 57 alleles. Diabetologia 1992; 35:583-588.
55. Ikegami H, Tahara Y, Topyon C, et al. Aspartic acid at position 57 of the HLA-DQ beta chain is not protective against insulin-dependent diabetes mellitus in Japanese people. J Autoimmunity 1990; 3:167-174.
56. Park Y, She JX, Wang CY, et al. Common susceptibility and transmission pattern of human leukocyte antigen DRB1-DQB1 haplotypes to Korean and Caucasian patients with Type 1 diabetes. J Clin Endocrinol Metab 2000; 85(12):4538-4542.
57. Dorman JS, LaPorte RE, Stone RA, Trucco M. Worldwide differences in the incidence of type I diabetes are associated with amino acid variation at position 57 of the HLA-DQ beta chain. Proc Natl Acad Sci USA 1990; 87:7370-7374.
58. She JX. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today 1996; 17(7):323-329.
59. Melanitou E, Fain P, Eisenbarth GS. Genetics of type 1A (immune mediated) diabetes. J Autoimmun 2003; 21(2): 93-98.
60. Warram JH, Krolewski AS, Gottlieb MS, Kahn CR. Differences in risk of insulin-dependent diabetes in offspring of diabetic mothers and diabetic fathers. N Engl J Med 1984; 311:149-152.
61. Vadheim CM, Rotter JI, Maclaren NK, Riley WJ, Anderson CE. Preferential transmission of diabetic alleles within the HLA gene complex. N Engl J Med 1986; 315: 1314-1318.
62. She JX, MarronMP. Genetic susceptibility factors in Type 1 diabetes: linkage, disequilibrium and functional analyses. Curr Opin Immunol 1998; 10(6):682-689.
63. Davies JL, Kawaguchi Y, Bennett ST, et al. A genome-wide search for human Type 1 diabetes susceptibility genes. Nature 1994; 371(6493):130-136.
64. Buzzetti R, Quattrocchi CC, Nistico L. Dissecting the genetics of Type 1 diabetes: relevance for familial clustering and differences in incidence. Diabetes Metab Rev 1998; 14(2):111-128.
65. Luo DF, Buzzetti R, Rotter JI, et al. Confirmation of three susceptibility genes to insulin-dependent diabetes mellitus: IDDM4, IDDM5 and IDDM8. Hum Mol Genet 1996; 5(5):693-698.
66. Pugliese A. Unraveling the genetics of insulin-dependent type 1A diabetes: the search must go on. Diabetes Rev 1999; 7:39-54.
67. MarronMP, Zeidler A, Raffel LJ, et al. Genetic and physical mapping of a Type 1 diabetes susceptibility gene (IDDM12) to a 100-kb phagemid artificial chromosome clone containing D2S72-TLA4-D2S105 on chromosome 2q33. Diabetes 2000; 49(3):492-499.
68. Maier LM, Wicker LS. Genetic susceptibility to Type 1 diabetes. Curr Opin Immunol 2005; 17(6):601-608.
69. Vaidya B, Pearce S. The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. Eur J Endocrinol 2004; 150(5):619-626.
70. Kim MS, Polychronakos C. Immunogenetics of Type 1 diabetes. Horm Res 2005; 64(4):180-188.
71. Concannon P, Erlich HA, Julier C, et al. Type 1 Diabetes Genetics Consortium. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes 2005; 54(10):2995-3001.
72. She JX, Bui MM, Tian XH, et al. Additive susceptibility to insulin-dependent diabetes conferred by HLA-DQB1 and insulin genes. Autoimmunity 1994; 18(3):195-203.
73. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984; 33(2):176-183.
74. Cerrone GE, Caputo M, Lopez AP, et al. Variable number of tandem repeats of the insulin gene determines susceptibility to latent autoimmune diabetes in adults. Mol Diagn 2004; 8(1):43-49.
75. Pugliese A, Zeller M, Fernandez A Jr., et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for Type 1 diabetes. Nat Genet 1997; 15(3):293-297.
76. Vafiadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997; 15(3):289-292.
77. Barratt BJ, Payne F, Lowe CE, et al. Remapping the insulin gene/IDDM2 locus in Type 1 diabetes. Diabetes 2004; 53(7):1884-1889.
78. Tait KF, Collins JE, Heward JM, et al. Evidence for a Type 1 diabetes-specific mechanism for the insulin geneassociated IDDM2 locus rather than a general influence on autoimmunity. Diabet Med 2004; 21(3):267-270.
79. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423(6939):506-511.
80. Barbesino G, Chiovato L. The genetics of Hashimoto’s disease. Endocrinol Metab Clin North Am 2000; 29(2): 357-374.
81. Kotsa K, Watson PF, Weetman AP. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol (Oxf) 1997; 46(5):551-554.
82. Donner H, Braun J, Seidl C, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto’s thyroiditis and Addison’s disease. J Clin Endocrinol Metab 1997; 82(12):4130-4132.
83. Braun J, Donner H, Siegmund T, Walfish PG, Usadel KH, Badenhoop K. CTLA-4 promoter variants in patients with Graves’ disease and Hashimoto’s thyroiditis. Tissue Antigens 1998; 51(5):563-566.
84. Simmonds MJ, Gough SC. Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond. Clin Exp Immunol 2004; 136(1):1-10.
85. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36(4):337-338.
86. Ladner MB, Bottini N, Valdes AM, Noble JA. Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with Type 1 diabetes. Hum Immunol 2005; 66(1):60-64.
87. Vang T, Congia M, Macis MD, et al. Autoimmuneassociated lymphoid tyrosine phosphatase is a gain-offunction variant. Nat Genet 2005; 37(12):1317-1319.
88. ZhengW, She JX. Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and Type 1 diabetes. Diabetes 2005; 54(3):906-908.
89. Smyth D, Cooper JD, Collins JE, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with Type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 53(11):3020-3023.
90. Akerblom HK, Knip M. Putative environmental factors in Type 1 diabetes. Diabetes Metab Rev 1998; 14:31-67.
91. Couper JJ, Steele C, Beresford S, et al. Lack of association between duration of breast-feeding or introduction of cow’s milk and development of islet autoimmunity. Diabetes 1999; 48(11):2145-2149.
92. Graves PM, Barriga KJ, Norris JM, et al. Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care 1999; 22(10):1694-1697.
93. Maclaren NK, Atkinson MA. Insulin-dependent diabetes mellitus: the hypothesis of molecular mimicry between islet cell antigens and microorganisms. Mol Med Today 1997:76-83.
94. Law GR, McKinney PA, Staines A, et al. Clustering of childhood IDDM. Links with age and place of residence. Diabetes Care 1997; 20(5):753-756.
95. Honeyman MC, Coulson BS, Stone NL, et al. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing Type 1 diabetes. Diabetes 2000; 49(8):1319-1324.
96. Hyoty H, Hiltunen M, Knip M, et al. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes 1995; 44(6): 652-657.
97. Vreugdenhil GR, Schloot NC, Hoorens A, et al. Acute onset of type I diabetes mellitus after severe echovirus 9 infection: putative pathogenic pathways. Clin Infect Dis 2000; 31(4):1025-1031.
98. Maclaren NK, Atkinson MA. Is insulin-dependent diabetes mellitus environmentally induced? N Engl J Med 1992; 327:347-349.
99. Karjalainen J, Martin J, Knip M. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med 1992; 327:302-307.
100. Verge CF, Gianani R, Yu L, et al. Late progression to diabetes and evidence for chronic beta-cell autoimmunity in identical twins of patients with type I diabetes. Diabetes 1995; 44(10):1176-1179.
101. KrokowskiM, Caillat-Zucman S, Timsit J, et al. Anti-bovine serum albumin antibodies: genetic heterogeneity and clinical relevance in adult-onset IDDM. Diabetes Care 1995; 18(2):170-173.
102. Hummel M, Fuchtenbusch M, SchenkerM, Ziegler AG.No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study. Diabetes Care 2000; 23(7): 969-974.
103. Cainelli F, Manzaroli D, Renzini C, Casali F, Concia E, Vento S. Coxsackie B virus-induced autoimmunity to GAD does not lead to Type 1 diabetes. Diabetes Care 2000; 23(7):1021-1022.
104. Casu A, Carlini M, Contu A, Bottazzo GF, Songini M. Type 1 diabetes in Sardinia is not linked to nitrate levels in drinking water. Diabetes Care 2000; 23(7):1043-1044.
105. Lonnrot M, Korpela K, Knip M, et al. Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes 2000; 49(8): 1314-1318.
106. Juhela S, Hyoty H, Roivainen M, et al. T-cell responses to enterovirus antigens in children with Type 1 diabetes. Diabetes 2000; 49(8):1308-1313.
107. Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 34:151-156.
108. Rabin DU, Pleasic SM, Shapiro JA, et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 1994; 152(6): 3183-3188.
109. Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1996; 93(13): 6367-6370.
110. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222(4630):133-139.
111. Winter WE. The use of islet autoantibody markers in the prediction of autoimmune Type 1 diabetes. Clin Immunol Newslett 1999; 19(3):25-39.
112. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell autoantibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2:1279-1283.
113. Nayak RC, Omar MAK, Rabizadeh A, Srikanta S, Eisenbarth GS. '‘Cytoplasmic’' islet cell antibodies. Evidence that the target antigen is a sialoglycoconjugate. Diabetes 1985; 34:617-619.
114. Richter W, Seissler J, Northemann W, Wolfahrt S, Meinch H-M, Scherbaum WA. Cytoplasmic islet cell antibodies recognize distinct islet antigens in IDDM but not in stiff man syndrome. Diabetes 1993; 42:1642-1648.
115. Schatz DA, Barrett DJ, Maclaren NK, Riley WJ. Polyclonal nature of islet cell antibodies in insulin-dependent diabetes. Autoimmunity 1988; 1:45-50.
116. Neufeld M, Maclaren NK, Riley WJ, et al. Islet cell and other organ-specific antibodies in U.S. Caucasians and Blacks with insulin-dependent diabetes mellitus. Diabetes 1980; 29:589-592.
117. Schatz D, Krischer J, Horne G, et al. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. J Clin Invest 1994; 93:2403-2407.
118. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with Type 1 diabetes mellitus. N Engl J Med 2002; 346:1685-1691.
119. Skyler JS, Krischer JP, Wolfsdorf J, et al, Diabetes Prevention Trial-Type 1 Study Group. Effects of oral insulin in relatives of patients with Type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005; 28(5):1068-1076.
120. Irvine WJ, McCallum CJ, Gray RS, Duncan LJP. Clinical and pathogenic significance of pancreatic islet-cell antibodies in diabetics treated with oral hypoglycemic agents. Lancet 1977; 1:1025-1027.
121. Di Mario U, Irvine WJ, Borsey DQ, Kyner JL, Weston J, Galfo C. Immune abnormalities in diabetic patients not requiring insulin at diagnosis. Diabetologia 1983; 25: 392-395.
122. Niskanen L, Karjalaienen J, Sarlund H, Siitonen O, Uusitupa M. Five year follow-up of islet-cell antibodies in (non-insulin dependent) diabetes mellitus. Diabetologia 1991; 34:402-408.
123. Riley WJ, Maclaren NK, Krischer J, et al. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N Engl J Med 1990; 323:1167-1172.
124. Krischer JP, Cuthbertson DD, Yu L, et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with Type 1 diabetes. J Clin Endocrinol Metab 2003; 88(1):103-108.
125. Palmer JP. Predicting IDDM: use of humoral immune markers. Diabetes Rev 1993; 1:104-115.
126. Decochez K, Keymeulen B, Somers G, et al. Use of an islet cell antibody assay to identify Type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. Diabetes Care 2000; 23(8):1072-1078.
127. Torn C, Landin-Olsson M, Lernmark A, et al. Prognostic factors for the course of B cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000; 85(12):4619-4623.
128. Vives-Pi M, Somoza N, Vargas F, et al. Expression of glutamic acid decarboxylase (GAD) in the alpha, beta and delta cells of normal and diabetic pancreas: implications for the pathogenesis of type I diabetes. Clin Exp Immunol 1993; 92(3):391-396.
129. Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in insulindependent diabetes mellitus. J Clin Invest 1992; 89: 283-292.
130. Hagopian WA, Michelsen B, Karlsen AE, et al. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase. Diabetes 1993; 42(4):631-636.
131. Luhder F, Schlosser M, Mauch L, et al. Autoantibodies against GAD65 rather than GAD67 precede the onset of Type 1 diabetes. Autoimmunity 1994; 19(2):71-80.
132. Hampe CS, Hammerle LP, Bekris L, et al. Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different gad antibody-positive phenotypes. J Clin Endocrinol Metab 2000; 85(12):4671-4679.
133. Atkinson MA, Kaufman DL, Campbell L. Response of peripheral blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 1992; 339: 458-459.
134. Roep BO, Arden SD, de Vries RR, Hutton JC. T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. Nature 1990; 345:632-634.
135. Roep BO, Kallan AA, Duinkerken G, et al. T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM. Diabetes 1995; 44:278-283.
136. Hummel M, Durinovic-Bello I, Ziegler A-G. Relation between cellular and humoral immunity to islet cell antigens in type I diabetes. J Autoimmun 1996; 9: 427-430.
137. Harrison LC, Honeyman MC, DeAizpurua HJ, et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 1993; 341:1365-1369.
138. Atkinson MA, Maclaren NK, Scharp DW, Lacy PE, Riley WJ. 64 000 Mr autoantibodies as predictors of insulindependent diabetes. Lancet 1990; 335:1357-1360.
139. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42:359-362.
140. Seissler J, de Sonnaville JJ, Morgenthaler NG, et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998; 41(8): 891-897.
141. Carlsson A, Sundkvist G, Groop L, Tuomi T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 2000; 85(1):76-80.
142. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M. Evidence of islet cell autoimmunity in elderly patients with Type 2 diabetes. Diabetes 2000; 49(1):32-38.
143. Payton MA, Hawkes CJ, Christie MR. Relationship of the 37,000-and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 1995; 96(3):1506-1511.
144. Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetesrelated 37/40K autoantigen and a target of islet-cell antibodies. J Immunol 1995; 155(11):5419-5426.
145. Lu J, Li Q, Xie H, et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci USA 1996; 93(6):2307-2311.
146. Greenbaum CJ, Palmer JP, Kuglin B, Kolb H. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab 1992; 74(5):1040-1044.
147. Levy-Marchal C, Bridel MP, Sodoyez-Goffaux F, et al. Superiority of radiobinding assay over ELISA for detection of IAAs in newly diagnosed type I diabetic children. Diabetes Care 1991; 14(1):61-63.
148. Atkinson MA, Maclaren NK, Riley WJ, Winter WE, Fisk DD, Spillar RP. Are insulin autoantibodies markers for insulin-dependent diabetes mellitus? Diabetes 1986; 35: 894-898.
149. Castano L, Russo E, Zhou L, Lipes MA, Eisenbarth GS. Identification and cloning of a granule autoantigen (carboxypeptidase-H) associated with type I diabetes. J Clin Endocrinol Metab 1991; 3:1197-1201.
150. Rorsman F, Husebye ES, Winqvist O, Bjork E, Karlsson FA, Kampe O. Aromatic-L-amino-acid decarboxylase, a pyridoxal phosphate-dependent enzyme, is a beta-cell autoantigen. Proc Natl Acad Sci USA 1995; 92(19): 8626-8629.
151. Kim YJ, Zhou Z, Hurtado J, et al. IDDM patients’ sera recognize a novel 30-kD pancreatic autoantigen related to chymotrypsinogen. Immunol Invest 1993; 22(3):219-222.
152. Chang YH, Hwang J, Shang HF, Tsai ST. Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM. Diabetes 1996; 45(4): 408-414.
153. Aanstoot HJ, Kang SM, Kim J, et al. Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in Type 1 diabetes. J Clin Invest 1996; 97(12):2772-2783.
154. Johnson JH, Crider BP, McCorkle K, Alford M, Unger RH. Inhibition of glucose transport into rat islet cells by immunoglobulins from patients with new-onset insulin-dependent diabetes mellitus. N Engl JMed 1990; 332:653-659.
155. Atkinson MA, Holmes LA, Scharp DW, Lacy PE, Maclaren NK. No evidence for serological autoimmunity to islet cell heat shock proteins in insulin dependent diabetes. J Clin Invest 1991; 8:21-24.
156. Pietropaolo M, Castaño L, Babu S, et al. Islet cell autoantigen 69 kD (ICA69): molecular cloning and characterization of a novel diabetes-associated autoantigen. J Clin Invest 1993; 92:359-371.
157. Lampasona V, Ferrari M, Bosi E, Pastore MR, Bingley PJ, Bonifacio E. Sera from patients with IDDM and healthy individuals have antibodies to ICA69 on western blots but do not immunoprecipitate liquid phase antigen. J Autoimmun 1994; (5):665-664.
158. Maron R, Elias D, DeJongh BM, et al. Autoantibodies to the insulin receptor in juvenile onset insulin-dependent diabetes. Nature 1983; 303:81-88.
159. Pak CY, Cha CY, Rajotte RV, McArthur RG, Yoon JW. Human pancreatic islet cell specific 38 kilodalton autoantigen identified by cytomegalovirus-induced monoclonal islet cell autoantibody. Diabetologia 1990; 33(9):569-572.
160. Karounos DG, Thomas JW. Recognition of common islet antigen by autoantibodies from NOD mice and humans with IDDM. Diabetes 1990; 39(9):1085-1090.
161. Lernmark A, Freedman ZR, Hofmann C, et al. Islet-cellsurface antibodies in juvenile diabetes mellitus. N Engl J Med 1978; 299:375-380.
162. Maclaren NK, Huang S-W. Antibody to cultured human insulinoma cells in insulin-dependent diabetes. Lancet 1975; 1:997-999.
163. Bohmer K, Keilacker H, Kuglin B, et al. Proinsulin autoantibodies are more closely associated with type 1 (insulin-dependent) diabetes mellitus than insulin autoantibodies. Diabetologia 1991; 34(11):830-834.
164. Kasimiotis H, Myers MA, Argentaro A, et al. Sexdetermining region Y-related protein SOX13 is a diabetes autoantigen expressed in pancreatic islets. Diabetes 2000; 49(4):555-561.
165. Winter WE. Autoimmune disorders that influence carbohydrate metabolism. In: Nakamura RM, Keren DF, Bylund DJ, eds. Clinical and Laboratory Evaluation of Human Autoimmune Diseases. Chicago, IL: ASCP Press, 2002:345-372.
166. Bottazzo GF, Lendrum R. Separate autoantibodies to human pancreatic glucagon and somatostatin cells. Lancet 1976; 2:873-876.
167. Del Prete GF, Tiengo A, Nosadini R, Bottazzo GF, Betterle C, Bersani G. Glucagon secretion in two patients with autoantibodies to glucagon producing cells. Horm Metab Res 1978; 10:260-261.
168. Winter WE, Maclaren NK, Riley WJ, Unger, RH, Ozand P, Neufeld M. Pancreatic alpha cell autoantibodies and glucagon response to arginine. Diabetes 1984; 33: 435-437.
169. Baba S, Morita S, Mizuno N, Okada K. Autoimmunity to glucagon in a diabetic not on insulin. Lancet 1976; 12:585.
170. Sanke T, Kondo M, Moriyama Y, Nanjo K, Iwo K, Miyamura K. Glucagon binding autoantibodies in a patient with hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1983; 57:1140-1144.
171. Jackson RA, Haynes BF, Burch WM, Shimizu K, Bowring MA, Eisenbarth GS. Iap T cells in new onset Graves’ disease. J Clin Endocrinol Metab 1984; 59:187-190.
172. Jackson RA, Morris MA, Haynes BF, Eisenbarth GS. Increased circulating Ia-antigen bearing T-cells in type I diabetes mellitus. N Engl J Med 1982; 306:785-788.
173. Serjeantson S, Theophilus J, Zimmet P, Court J, Corssley JR, Elliott RB. Lymphocytotoxic antibodies and histocompatibility antigens in juvenile-onset diabetes mellitus. Diabetes 1981; 30:26-29.
174. Virella G, Wohltmann H, Sagel J, et al. Soluble immune complexes in patients with diabetes mellitus: detection and pathological significance. Diabetologia 1981; 21: 184-191.
175. Zier KS, Keo MM, Speilman RS, Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes 1984; 33:552-555.
176. Schatz DA, Riley WJ, Maclaren NK, Barrett DJ. Defective inducer T-cell function before the onset of insulin-dependent diabetes mellitus. J Autoimmun 1991; 4:125-136.
177. Faustman D, Li XP, Lin HY, et al. Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. Science 1991; 254(5039):1756-1761.
178. Lang F, Maugendre D, Houssaint E, Charbonnel B, Sai P. Cytoadherence of lymphocytes from type I diabetic subjects to insulin-secreting cells. Marker of anti-beta-cell cellular immunity. Diabetes 1987; 36(12):1356-1364.
179. Litherland SA, Xie XT, Hutson AD, et al. Aberrant prostaglandin synthase 2 expression defines an antigenpresenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest 1999; 104(4):515-523.
180. Litherland SA, Xie TX, Grebe KM, Li Y, Moldawer LL, Clare-Salzler MJ. IL10 resistant PGS2 expression in at-risk/Type 1 diabetic human monocytes. J Autoimmun 2004; 22(3):227-233.
181. Riley WJ, Maclaren NK, Lezotte D, Spillar RP, Rosenbloom AL. Thyroid autoimmunity in insulindependent diabetes mellitus: the case for routine screening. J Pediatr 1981; 98:350-354.
182. McCanlies E, O’Leary LA, Foley TP, et al. Ashimoto’s thyroiditis and insulin-dependent diabetes mellitus: differences among individuals with and without abnormal thyroid function. J Clin Endocrinol Metab 1998; 83(5): 1548-1551.
183. Riley WJ, Toskes PP, Maclaren NK, Silverstein JS. Predictive value of gastric parietal cell autoantibodies as a marker for gastric and hematological abnormalities associated with insulin-dependent diabetes. Diabetes 1982; 32:1051-1055.
184. Riley WJ, Winer A, Goldstein D. Coincident presence of thyrogastric autoimmunity at onset of Type 1 (insulindependent) diabetes. Diabetologia 1983; 24:418-421.
185. Nepom GT, Kwok WW. Molecular basis for HLA-DQ associations with IDDM. Diabetes 1998; 47(8):1177-1184.
186. Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985; 34:1306-1308.
187. Silverstein J, Maclaren N, RileyW, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988; 319:599-604.
188. Martin S, Schernthaner G, Nerup J, et al. Follow-up of cyclosporin A treatment in Type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 1991; 34(6):429-434.
189. Silverstein JH, Rosenbloom AL. New developments in Type 1 (insulin-dependent) diabetes. Clin Pediatr 2000; 39:257-266.
190. Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998; 41(5):536-541.
191. Pozzilli P, Pitocco D, Visalli N, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000; 43(8):1000-1004.
192. Hahl J, Simell T, Ilonen J, Knip M, Simell O. Costs of predicting IDDM. Diabetologia 1998; 41(1):79-85.
193. Kupila A, Sipila J, Keskinen P, et al. Intranasally administered insulin intended for prevention of Type 1 diabetes-a safety study in healthy adults. Diabetes Metab Res Rev 2003; 19(5):415-420.
194. Elliott RB, Chase HP. Prevention or delay of Type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34(5):362-365.
195. ENDIT Trial: European Nicotinamide Intervention Trial (Manna R, Migliore A, Martin LS, et al.). Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Br J Clin Pract 1992; 46(3):1-9.
196. Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of Type 1 diabetes. Lancet 2004; 363(9413):925-931.
197. Herskowitz RD, Jackson RA, Soeldner JS, Eisenbarth GS. Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide. J Autoimmun 1989; 2(5): 733-737.
198. Vidal J, Fernandez-Balsells M, Sesmilo G, et al. Effects of nicotinamide and intravenous insulin therapy in newly diagnosed Type 1 diabetes. Diabetes Care 2000; 23(3): 360-364.
199. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N Engl J Med 2002; 346(22):1692-1698.
200. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes 2005; 54(6): 1763-1769.
201. Pozzilli P. Prevention of insulin-dependent diabetes mellitus Diabetes Metab Rev 1998; 14(1):69-84.
202. Rosenbloom AL, Schatz DA, Krischer JP, et al. Therapeutic controversy: prevention and treatment of diabetes in children. J Clin Endocrinol Metab 2000; 85(2): 494-522.
203. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343(4):230-238.
204. Yang L, Li S, Hatch H, et al. In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc Natl Acad Sci USA 2002; 99(12):8078-8083.
205. Chaudhari M, Cornelius JG, Schatz D, Peck AB, Ramiya VK. Pancreatic stem cells: a therapeutic agent that may offer the best approach for curing Type 1 diabetes. Pediatr Diabetes 2001; 2(4):195-202.
206. Peck AB, Ramiya V. In vitro-generation of surrogate islets from adult stem cells. Transpl Immunol 2004; 12(3-4): 259-272.
207. Peck AB, Yin L, Ramiya V. Animal models to study adult stem cell-derived, in vitro-generated islet implantation. ILAR J 2004; 45(3):259-267.
208. Larsen JL. Pancreas transplantation: indications and consequences. Endocr Rev 2004; 25(6):919-946.
209. Demartines N, Schiesser M, Clavien PA. An evidencebased analysis of simultaneous pancreas-kidney and pancreas transplantation alone. Am J Transplant 2005; 5(11):2688-2697.
210. Kim KW. Islet transplantation: a realistic alternative for the treatment of insulin deficient diabetes mellitus. Diabetes Res Clin Pract 2004; 66(suppl 1):S11-S117.
211. Yamada S, Kojima I. Regenerative medicine of the pancreatic beta cells. J Hepatobiliary Pancreat Surg 2005; 12(3):218-226.
212. Zhang YQ, Kritzik M, Sarvetnick N. Identification and expansion of pancreatic stem/progenitor cells. J Cell Mol Med 2005; 9(2):331-344.
213. Di Gioacchino G, Di Campli C, Zocco MA, et al. Transdifferentiation of stem cells in pancreatic cells: state of the art. Transplant Proc 2005; 37(6):2662-2663.
214. Calne R. Cell transplantation for diabetes. Philos Trans R Soc Lond B Biol Sci 2005; 360(1461):1769-1774.
215. Stainer D. No stem cell is an islet (yet). N Engl J Med 2006; 354(5):521-523.
216. Trucco M. Regeneration of the pancreatic beta cell. J Clin Invest 2005; 115(1):5-12.
217. Umpierrez G, Casals MMC, Gebhart SSP, et al. Diabetic ketoacidosis in obese African Americans. Diabetes 1995; 44(7):790-795.
218. Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care 1997; 20(4):484-486.
219. Banerji MA. Impaired beta-cell and alpha-cell function in African-American children with Type 2 diabetes mellitus-'' Flatbush diabetes’'. J Pediatr Endocrinol Metab 2002; 15(suppl 1):493-501.
220. Zdravkovic V, Daneman D, Hamilton J. Presentation and course of Type 2 diabetes in youth in a large multi-ethnic city. Diabet Med 2004; 21(10):1144-1148.
221. Sapru A, Gitelman SE, Bhatia S, Dubin RF, Newman TB, Flori H. Prevalence and characteristics of Type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab 2005; 18(9):865-872.
222. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulindependent diabetes mellitus. N Engl J Med 1989; 320(9): 550-554.
223. Dupre J, Mahon JL. Diabetes-related autoantibodies and the selection of subjects for trials of therapies to preserve pancreatic beta-cell function in recent-onset Type 1 diabetes. Diabetes Care 2000; 23(8):1057-1058.
224. Rabinovitch A, Skyler JS. Prevention of Type 1 diabetes. Med Clin North Am 1998; 82(4):739-755.
225. Bonifacio E, Genovese S, Braghi S, et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 1995; 38(7):816-822.
226. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45(7):926-933.
227. Maclaren N, Lan M, Coutant R, et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives. J Autoimmun 1999; 12(4):279-287.
228. Gardner SG, Gale EA, Williams AJ, et al. Progression to diabetes in relatives with islet autoantibodies. Is it inevitable? Diabetes Care 1999; 22(12):2049-2054.